@FierceBiotech: In January, Levin dumped Teva's immunotherapy program. Now, checkpoint receptor drugs are all the rage. More | Follow @FierceBiotech
@JohnCFierce: Galderma Labs axing staff in U.S. shakeup after president exits (gee, the rumors were true). News | Follow @JohnCFierce
@DamianFierce: Imagine being the Novartis worker who picked up Retrophin's call. "Hey, so, remember Syntocinon?" | Follow @DamianFierce
@EmilyMFierce: Congressional budget deal would restore NIH sequester cuts. Coverage | Follow @EmilyMFierce
> Synta Pharmaceuticals ($SNTA) is touting early results for the breast cancer-treating ganetespib, its lead candidate, pointing to interim Phase II data in which the treatment posted a 75% response rate among HER2-positive patients. Release
> Rockville, MD's Emergent BioSolutions ($EBS) has signed a deal to buy Cangene for $222 million, acquiring the company's line of biodefense therapeutics and infectious disease treatments. More
@FierceMedDev: Avinger draws new financing to back testing of light-enhanced PAD catheter. Article | Follow @FierceMedDev
@MarkHFierce: St. Jude Medical won a CE mark for a larger size of its Portico heart valve, adding to a now-crowded competition. More | Follow @MarkHFierce
@MichaelGFierce: AdvaMed, MDMA commend congressional budget deal as vote approaches. Story | Follow @MichaelGFierce
@GalenMoore: Senesco Announces up to $25.2 Million Equity Financing. Release | Follow @GalenMoore
> Boston Scientific's Watchman stroke-fighting device wins overwhelming FDA panel support. Piece
> T2 brings on 2 Hologic vets as work continues on Candida assay ramp-up. News
Pharma News
@FiercePharma: India's Lupin already launched its copies of Eli Lilly's $5B antidepressant, Cymbalta, in U.S. Half-dozen companies got FDA nod. Poor Lilly. | Follow @FiercePharma
@EricPFierce: Merck KGaA's Allergopharma unit building a €40M plant near Hamburg that will make #allergy meds for China. Release | Follow @EricPFierce
@CarlyHFierce: Here come the Cymbalta copies. FDA approves generics from Teva, Sun, Dr. Reddy's, Lupin and others. Release | Follow @CarlyHFierce
> Think fast: A new cognition study could add $350M to Lundbeck's Brintellix sales. News
> D-Day for Eli Lilly: Generic foes arrive for $5B antidepressant Cymbalta. Article
Vaccines News
> GSK shares data from pivotal PhIII trial of quadrivalent flu vaccine. Story
> Novartis awaits pivotal Bexsero decisions in Canada and Europe. Piece
> Genocea begins a PhI trial of its rival to Pfizer's Prevnar. News
> AstraZeneca eyes 2014 EU launch for 4-in-1 flu vaccine after winning approval. More
> Pentagon tasks Pfizer with radically rethinking vaccine development. Article
> Lundbeck teams with Otsuka on Alzheimer's vaccine development. Item
Pharma Manufacturing News
> ScinoPharma's $113 million China API plant ready to go. News
> Merck KGaA targets China with a planned €40M allergy plant. More
> FDA stationing 10 new drug inspectors in China. Story
> GSK's new manufacturing investments in the U.K. now pass $1 billion. Article
> Cardinal, CVS JV creates more upheaval in U.S. drug supply chain. Piece
> FDA warns NJ lotion maker: Your water does not meet specs. Item